T cell immunotherapy: addressing toxicity issues in a rapidly commercializing field
Immuno-Oncology Insights 2020; 1(3), 191–196
Published: 15 January 2021
John Rossi joined Kite in 2015 after 13 years at Amgen. He is currently a Senior Director in the Department of Translational Medicine at Kite and leads pharmacology activities related to the clinical development of Kite’s cell therapy pipeline. At Kite, he has built an effective translational team to support the clinical development of axicabtagene ciloleucel (Yescarta) and KTE-X19 (Tecartus). His team has contributed directly to the regulatory approval of these products through pharmacokinetic and pharmacodynamic evaluation. Among many achievements at Kite, he has represented the organization through external scientific presentations and collaborative manuscripts with leading academic researchers such as Steven Rosenberg and James Kochenderfer at the NCI. Accomplishments include the discovery of metrics to characterize CAR T based on functionality, novel biomarker knowledge of how CARs work in the clinic, mechanistic information on toxicities and insights into the biology of the TME, including immune checkpoints, and the role of IL-15 in the context of CAR T-cell function.